what are the latest developments in CDK4/6 inhibition? Dr Olivier - PowerPoint PPT Presentation

ESMO Congress webinar HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition? Dr Olivier Trédan Head of the Oncology Department at Centre Léon-Bérard, Lyon, France Recorded October 2019 This activity is supported by an educational grant from Eli Lilly and Company.

Disclaimer Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

Learning objectives • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Webinar overview HR+/HER2- advanced breast cancer • The clinical efficacy and safety of CDK4/6 inhibitors • ESMO Congress 2019 – What are the latest data for CDK4/6 inhibitors? • ESMO Congress 2019 – Can patient or disease characteristics predict responsiveness to CDK4/6 inhibitors? • ESMO Congress 2019 – The expanding armamentarium of therapies for advanced breast cancer CDK, cyclin-dependent kinase.

The clinical efficacy and safety of CDK4/6 inhibitors Focus on CDK4/6 inhibitors for HR+/HER2- advanced breast cancer CDK, cyclin-dependent kinase; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive.

Clinical trials demonstrate the benefit of CDK4/6 inhibitors, especially when combined with endocrine therapy In key clinical trials, CDK4/6 inhibitors demonstrated significant improvements in PFS vs. placebo for the treatment of HR+/HER2- advanced breast cancer PALOMA-2 + letrozole (N=666) PFS = 27.6 vs. placebo 14.5, HR 0.56 (CI 0.46 – 0.69) Palbociclib PALOMA-3 + fulvestrant (second-line) (N=521) PFS = 11.2 vs. placebo 4.6, HR 0.50 (CI 0.40 – 0.62) MONALEESA-2 + letrozole ( N=668), PFS = 25.3 vs. placebo 16.0, HR 0.57 (CI 0.46 – 0.70) Ribociclib MONALEESA-3 + fulvestrant (2nd-line) (n=343), PFS = 14.6 vs. placebo 9.1, HR 0.57 (CI 0.43 – 0.74) MONALEESA-7 + tamoxifen/NSAI + gos (N=672), PFS = 23.8 vs. placebo 13, HR 0.55 (CI 0.44 – 0.69) MONARCH-2 + fulvestrant (second-line) (N=669) PFS=16.4 vs. placebo 9.3, HR 0.55 (CI 0.45 – 0.68) Abemaciclib MONARCH-3 + letrozole/anastrozole (N=493) PFS=28.8 vs. placebo 14.8, HR 0.54 (CI 0.42 – 0.70) More ongoing Phase II and III clinical studies are testing CDK4/6 inhibitors either as monotherapy or in combination with other targeted therapies in HR+/HER2- advanced breast cancer CDK, cyclin-dependent kinase; CI, confidence interval; gos, goserelin; HER2-, human epidermal growth factor receptor 2 negative; HR, hazard ratio; HR+, hormone receptor positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival. Finn, N Engl J Med 2016; Rugo H, SABCS 2017; Hortobagyi G, N Engl J Med 2016 & Ann Oncol 2018; Goezt M, J Clin Oncol 2017 & AACR 2018; Tripathy D. Lancet Oncol. 2018;19:904 – 915; Turner N, N Engl J Med 2015, updated SABCS 2016; Cristofanilli M, Lancet Oncol 2016; Sledge, J Clin Oncol 2017; Slamon DJ, ASCO 2018 & J Clin Oncol. 2018.

Safety profiles of CDK4/6 inhibitors in advanced breast cancer Grade 3 – 4 neutropenia and leucopenia are are commonly reported for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer Palbociclib Ribociclib Abemaciclib PALOMA-2 2 MONALEESA-2 1 MONARCH-3 3 Neutropenia (74%), Neutropenia (80%), Neutropenia (41%), Adverse events Leucopenia (33%), Leucopenia (39%), Diarrhoea (81%), Any Grade Nausea (52%) Nausea (35%) Nausea (39%) Adverse events Neutropenia (59%) Neutropenia (66%) Neutropenia (21%) Grade 3 – 4 Leucopenia (21%) Leucopenia (25%) Leucopenia (7.6%) CDK, cyclin-dependent kinase. 1. Hortobagyi GN, et al. New Engl J Med. Med 2016; 375 :1738 – 1748; 2. Finn RS, et al. N Engl J Med. 2016; 375 :1925 – 1936; 3. Goetz MP, et al. J Clin Oncol. 2017; 35 :3638 – 3646.

ESMO CONGRESS 2019 – What are the latest data for CDK4/6 inhibitors? Focus on CDK4/6 inhibitors for HR+/HER2- advanced breast cancer CDK, cyclin-dependent kinase; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive.

The first report of an overall survival benefit with a CDK4/6 inhibitor + endocrine therapy was presented at ASCO 2019 OS data from the MONALEESA-7 trial showed that ribociclib plus endocrine therapy demonstrated a clinically and statistically significant longer OS than endocrine therapy alone in premenopausal patients with HR+/HER2- ABC* MONALEESA-7 +either tamoxifen or an NSAI plus goserelin, (N=672), OS = NR vs. Ribociclib placebo 40.9, HR, 0.712 (95% CI, 0.54 – 0.95) p = 0.00973 ~29% relative reduction in risk of death *Pre-specified interim analysis: Data cut-off Nov 30, 2018 The median follow up was 34.6 months. In the treatment and placebo arms respectively: the number on treatment at data cut-off (N=173) was 116 and 57 patients; OS was evaluated after 192 deaths (83 and 109). ABC, advanced breast cancer; CDK, cyclin-dependent kinase; CI, confidence interval; ET, endocrine therapy; HER2- human epidermal receptor 2-negative; HR, hazard ratio; HR+ hormone receptor-positive; NE, not evaluable; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; PBO, placebo; RIB, ribociclib. Hurvitz SA, et al. Abstract LBA 1008. Presented at the ASCO Annual Meeting 2019.

Overall survival results of the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/ABC treated with fulvestrant ± ribociclib Slamon DJ, et al. To report OS and 1L progression-free survival results from the Phase III MONALEESA-3 trial Median follow-up was 39.4 months Data cut-off: 3 Jun 2019 Results RIB + FUL PBO + FUL Postmenopausal patients with HR+/HER2− ABC, in HR=0.724 Median OS, months Not 1L and 2L settings, were randomized 2:1 to: 40.0 95% CI, 0.568-0.924 (Per protocol) reached p = 0.00455 PBO RIB Not HR=0.700 + + OS in 1L subgroup 45.1 reached 95% CI, 0.479-1.021 FUL FUL OS in early-relapse/2L HR=0.730 40.2 32.5 subgroup 95% CI, 0.530-1.004 121 32 On treatment at Median PFS, months HR=0.546 data cut-off n (%) (25%) (13.2%) 33.6 19.2 1L subgroup 95% CI, 0.415-0.718 167 108 OS evaluated after The safety profile was consistent with previously published analyses 275 deaths (34.5%) (44.6%) These data, combined with results from MONALEESA-7, confirm the benefit of ribociclib in the first- and second-line settings in pre- and postmenopausal patients with HR+/HER2- ABC ABC, advanced breast cancer; CI, confidence interval; HER2- human epidermal receptor 2-negative; 1l, first line; FUL, fulvestrant; HR, hazard ratio; HR+, hormone receptor-positive; OS, overall survival; PBO, placebo; PFS, progression-free survival; RIB, ribociclib; 2L, second line. Slamon DJ, et al. Ann Oncol. 2019; 30 (suppl_5):v851 – v934.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer Sledge GW, et al. To report OS results of the prespecified interim analysis Median OS benefit At the prespecified interim analysis, 338 deaths (77% of the Pre/peri- and postmenopausal women with of 9.4 months planned 441 events) were observed in the ITT population advanced ET resistant HR+/ HER2-ABC Results ABE + FUL PBO + FUL N=669 patients were randomized 2:1: HR=0.757 Median OS, months 46.7 37.3 95% CI 0.606-0.945 (Per protocol) PBO ABE P = 0.0137 + + OS benefit was consistent in all stratification factors FUL FUL More pronounced effects were observed in subgroups of: Patients were stratified based on site of Time to Primary resistance to PFS2 metastasis (visceral, bone-only, or other) and Visceral disease chemotherapy prior ET (HR: 0.675; 95% CI: resistance to prior ET (primary vs secondary) (HR: 0.675) (HR: 0.622; 95% CI: (HR: 0.686) 0.558,0.816) 0.499, 0.775) Safety data were consistent with known abemaciclib safety profile TABE+FUL provided a significant and clinically meaningful median OS benefit to pre- or perimenopausal and postmenopausal patients with HR+/HER2- ABC with disease progression on ET, with no new safety signals observed ABC, advanced breast cancer; ABE, abemaciclib; CI, confidence interval; ET, endocrine therapy; FULV, fulvestrant; HER2- human epidermal receptor 2-negative; HR, hazard ratio; HR+ hormone receptor-positive; ITT, intent to treat; OS, overall survival; PBO, placebo. Sledge GW, et al. Ann Oncol. 2019; 30 (suppl_5):v851 – v934.